GUERBET (EPA:GBT) Appointment of Mr. Bernard Massiot as Chairman of the Executive Board of Guerbet Group

Transparency directive : regulatory news

11/01/2010 17:30

PRESS RELEASE

                   Appointment of Mr. Bernard Massiot

            Chairman of the Executive Board of Guerbet Group

Villepinte, 11 January 2010

The Supervisory Board of Guerbet that met on Monday, 11 January, under the
chairmanship of Mr. Jean-Jacques Bertrand, appointed Mr. Bernard Massiot as
chairman of the Executive Board of Guerbet, replacing Mr. Philippe Decazes. His
appointment is destined to provide new momentum to the Group in achieving its
objective of becoming a major player in the medical imaging sector.

The Supervisory Board unanimously thanked Mr. Philippe Decazes for the work he
has accomplished over 15 years on behalf of the Guerbet Group, first within the
Simafex subsidiary and then as a member of Group Management over the last
12 years. The Board paid homage to the results thus obtained in recent years.

Mr. Philippe Decazes will continue to support the Group's strategy as an advisor
to the new Chairman.

Mr. Bernard Massiot, 54 years of age, is a graduate of Paris-Dauphine University
and has a degree in Public Accounting. He began his career in audit and finance
and subsequently general management in sectors including the press and media,
industry (Northeast France) and services, primarily in France or in Europe.

Mr. Bernard Massiot has served as a Director of Guerbet Group since 1993 and as
Vice Chairman of the Supervisory Board since 2006. He is also, moreover, a
grandson of André Guerbet, the company's founder, and one of the nephews of
Doctor Michel Guerbet.

Mr. Bernard Massiot has accordingly resigned from his functions on the
Supervisory Board.

The Supervisory Board reaffirms its confidence in Guerbet's prospects for
development and the ability of Group teams to successfully meet the challenges
ahead.

Mr. Bernard Massiot stated: "The goal of all shareholders and employees of
Guerbet Group is to develop in the service of patients and healthcare systems. I
am personally delighted to support this ambition."

About Guerbet

Guerbet is the only pharmaceutical group worldwide fully dedicated to medical
imaging, with a comprehensive offering of x-ray, MRI contrast media and nuclear
medicine products. Its products assist medical professionals (radiologists,
cardiologists, oncologists, etc.) in better diagnosing and treating their
patients (cardiovascular, cancer, inflammatory and degenerative diseases).

To develop new products and assure its future growth, every year Guerbet devotes
significant resources to research and development with 180 R&D employees and an
amount equivalent to approximately 10% of sales. MRI and nuclear medicine are
key priorities of Guerbet's research programmes.

Guerbet is solidly positioned in Europe with a market share of 25% and is
expanding its presence in the United States, Latin America and Asia.

Guerbet, listed on Eurolist Euronext Paris in compartment B had sales in 2008 of
EUR321 million, with a total workforce of 1,270 employees.

For additional information about Guerbet, please consult: www.guerbet.com.

                             Media contact:
                   Amélie Pelletier, Thomas Doron
              3d Communication, +33 (0) 1 46 05 87 87
        apelletier@3dcommunication.fr, tdoron@3dcommunication.fr

GUERBET's latest news

20/03/2024 18:00

GUERBET (EPA:GBT) Appointment of Mr. Bernard Massiot as Chairman of the Executive Board of Guerbet Group

Transparency directive : regulatory news

GUERBET's latest news

Other stories